Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. - Test2 - elhamkhani - TriplyDB

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

http://www.wikidata.org/entity/Q37192391

about

Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives.The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response

P2860

Q37665488-E2CB721A-FD91-4BDF-A7FE-33873397621F Q39091822-283CB09D-BBF2-40A7-B072-58B6E37A2B94 Q45873027-C9BC33F5-873D-43F1-B39C-967FB7E246EA Q46386898-ECF1D61C-A4F1-457E-9954-0918EF2E48B9 Q49989774-DEB56CCA-2426-4DCD-A77B-BCA6F16CEA13 Q58779410-EBBF5D03-5044-4310-93A3-37C5D64A4B09

P2860

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

http://www.wikidata.org/entity/Q37192391

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Double epigenetic modulation o ...... r poor-risk relapsed lymphoma.

@en

Double epigenetic modulation o ...... r poor-risk relapsed lymphoma.

@nl

type

label

Double epigenetic modulation o ...... r poor-risk relapsed lymphoma.

@en

Double epigenetic modulation o ...... r poor-risk relapsed lymphoma.

@nl

prefLabel

Double epigenetic modulation o ...... r poor-risk relapsed lymphoma.

@en

Double epigenetic modulation o ...... r poor-risk relapsed lymphoma.

@nl

P1433

Q37192391-5F26BB58-5ED3-415C-B2BE-3778E404F1A7

P1476

Q37192391-323C191F-E0B9-48E8-BAAD-4E1E7E7063A1

P2093

Q37192391-060A955C-828C-40E6-8A4F-C21E4329DEE8

Q37192391-0C069914-4E4A-497C-979D-FDABDC7350B6

Q37192391-0E64A58D-E2D8-47C8-9CD9-DC45B4260D10

Q37192391-3BCC489B-C514-42AB-87A4-40F310A9DB5C

Q37192391-4C26BC7B-33B5-444A-A8B5-6D1C9D79582C

Q37192391-595D3656-7B73-4401-96BF-D5913BD7B8D2

Q37192391-6A1433E7-4C47-4DB0-A304-3DD35103C2BB

Q37192391-7E4A7EE1-90AC-4F5D-8F7B-CC7F280507F2

Q37192391-86CA9F57-BCFD-4F44-B709-2CC7E017BF24

Q37192391-8ABB790E-46F3-4842-957D-46370C22F8CC

P2860

Q37192391-1170CC87-9825-4E16-95C1-E49906E98B81

Q37192391-30C27BDB-37A1-4519-B03A-6B61A1EC8D7F

Q37192391-335231C2-141C-4322-AA7B-932829789367

Q37192391-35A1834E-F33F-4153-BA66-32F35291C75D

Q37192391-3CF13E4F-8395-4020-B7F7-B85CCBCCD20B

Q37192391-422E7D13-35D5-4D81-841D-9A5AF9C11E48

Q37192391-44CEA079-2E68-45D6-BA9C-F3218CC8731E

Q37192391-47A2EE34-EAC9-4702-8FFC-B6BCE36D7C8D

Q37192391-50E29D40-F393-45AD-BEA7-3AF0D3E607D3

Q37192391-6948FDAD-B37B-409B-A900-352495B06BD7

P304

Q37192391-C3F61046-FE4C-4EC7-8B31-9DCD57C4EF87

P31

Q37192391-76F6EE6D-48FB-4C95-9A76-5163809EDFC6

P356

Q37192391-A1532CBE-80F6-4E1C-9AC0-01EC45D5E5DD

P407

Q37192391-AF2E97F6-15C0-4296-AFDE-2391209D80FD

P433

Q37192391-639C71E4-E7B0-4752-ACE2-8A6F0315165A

P478

Q37192391-620499D7-D857-43DF-940A-9B04FB03503E

P50

Q37192391-220421FB-6B05-4F08-8D14-98A337D26C4B

Q37192391-3FC66B63-9D0C-4387-AEF2-932F59BF26C3

P577

Q37192391-2B6B6F0C-0A5B-4FDC-ABDA-4FF45495933A

P698

Q37192391-32537517-0C92-422E-9133-BD41695C6BB6

P921

Q37192391-6E721F91-2986-4D64-A7CE-412B48EF856F

P932

Q37192391-C7639284-9497-4CF1-ADCD-B2D3257F4315

P356

P1433

P1476

Double epigenetic modulation o ...... or poor-risk relapsed lymphoma

@en

P2093

Alan Myers

http://www.w3.org/2001/XMLSchema#string

Alison Gulbis

http://www.w3.org/2001/XMLSchema#string

Amin Alousi

http://www.w3.org/2001/XMLSchema#string

Benigno C Valdez

http://www.w3.org/2001/XMLSchema#string

Borje S Andersson

http://www.w3.org/2001/XMLSchema#string

Bouthaina Dabaja

http://www.w3.org/2001/XMLSchema#string

Elizabeth J Shpall

http://www.w3.org/2001/XMLSchema#string

Michelle Fanale

http://www.w3.org/2001/XMLSchema#string

Muzaffar Qazilbash

http://www.w3.org/2001/XMLSchema#string

Nina Shah

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Nonparametric Estimation from Incomplete Observations

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Anticancer activities of histone deacetylase inhibitors

Identification of a predictive biomarker for hematologic toxicities of gemcitabine.

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies

Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

Evaluation of survival data and two new rank order statistics arising in its consideration.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

P304

2680-2688

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.30100

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Chelsea C Pinnix

P577

2016-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27203405

http://www.w3.org/2001/XMLSchema#string

P921

P932

4992444

http://www.w3.org/2001/XMLSchema#string